ZLAB (Zai Lab) 10-Year Sharpe Ratio: N/A (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLAB Zai Lab Ltd ZLAB
68 GF Score
Price $18.49
GF Value $32.43
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zai Lab 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-08-04), Zai Lab's 10-Year Sharpe Ratio is Not available.

Zai Lab  (NAS:ZLAB) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Zai Lab 10-Year Sharpe Ratio Related Terms

ZLAB vs COAG, SLS, IOVA: 10-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Zai Lab's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zai Lab 10-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Zai Lab's 10-Year Sharpe Ratio falls into.


ZLAB
68GF Score
Zai Lab Ltd ZLAB
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.49 is trading 43% below its estimated GF Value™ of $32.43. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • 10-Year Sharpe Ratio: N/A
  • GF Value™: $32.43 vs. price of $18.49 (43% below fair value)
  • GF Score™: 68/100 with 7 warning signs

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
68GF Score

Get the complete analysis for ZLAB

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.49
Price
$32.43
GF Value